NYSEMKT: CLDICalidi Biotherapeutics Inc Stock
$0.46-0.01 (-2.13%)
Updated Apr 17, 2025
CLDI Price
$0.46
Fair Value Price
N/A
Market Cap
$13.18M
52 Week Low
$0.35
52 Week High
$4.90
P/E
-0.16x
P/B
8.59x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.14M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
7.96
Operating Cash Flow
-$20M
Beta
0.36
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CLDI Overview
First Light Acquisition Group, Inc. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets companies that provide technology-enabled solutions with high-growth, mission-critical applications in government and commercial markets. First Light Acquisition was incorporated in 2021 and is headquartered in Reston, VA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CLDI's potential to beat the market
- CLDI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CLDI
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CLDI news, forecast changes, insider trades & much more!
CLDI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CLDI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLDI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CLDI is poor value based on its book value relative to its share price (8.59x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
CLDI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CLDI due diligence checks available for Premium users.
Valuation
CLDI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
-177.72x
Market
27.98x
CLDI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.59x
Industry
4.05x
CLDI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLDI's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.1M
Profit Margin
0%
CLDI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.2M
Liabilities
$12.2M
Debt to equity
7.96
CLDI's short-term assets ($10.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLDI's short-term assets ($10.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLDI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
-$5.0k
Financing
$13.1M
CLDI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLDI vs Biotech Stocks
Calidi Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.